Nerlynx

Here's Why Puma Biotechnology Tanked 37.3% in November
Here's Why Puma Biotechnology Tanked 37.3% in November
Motley Fool
Puma Biotechnology
Nerlynx
breast cancer
Flag link:
CHMP reverses course on neratinib, handing Puma an unexpected win on European marketing vote — shares soar
CHMP reverses course on neratinib, handing Puma an unexpected win on European marketing vote — shares soar
Endpoints
Puma Biotechnology
Europe
CHMP
EMA
neratinib
Nerlynx
breast cancer
Flag link:
Puma shares plummet as results from key trial delayed
Puma shares plummet as results from key trial delayed
Biopharma Dive
Puma Biotechnology
earnings
Nerlynx
clinical trials
Flag link:
Why Puma Biotechnology Shares Jumped 15% Friday
Why Puma Biotechnology Shares Jumped 15% Friday
Motley Fool
Puma Biotechnology
earnings
Nerlynx
breast cancer
Flag link:
Watch These February Biotech Catalysts
Watch These February Biotech Catalysts
Seeking Alpha
biotech
Dynavax
HEPLISAV-B
vaccines
Novavax
NanoFlu
Nerlynx
Puma Biotechnology
breast cancer
Flag link:
Negligible Benefit Of Nerlynx, A New Breast Cancer Drug, Calls For Caution In Prescribing
Negligible Benefit Of Nerlynx, A New Breast Cancer Drug, Calls For Caution In Prescribing
Forbes
Nerlynx
breast cancer
Puma Biotechnology
Flag link:
Does Puma's quick Nerlynx launch play into its buyout prospects?
Does Puma's quick Nerlynx launch play into its buyout prospects?
Fierce Pharma
Puma Biotechnology
Nerlynx
breast cancer
M&A
Flag link:
FDA's Flashing Green Light Boosts Novel Drug Approvals
FDA's Flashing Green Light Boosts Novel Drug Approvals
Seeking Alpha
FDA
drug approvals
Gilead Sciences
Puma Biotechnology
Vosevi
Nerlynx
Flag link:
Does Puma Biotechnology's Approval Make It Worth More?
Does Puma Biotechnology's Approval Make It Worth More?
Motley Fool
Puma Biotechnology
Nerlynx
breast cancer
Flag link:
Puma granted broad label for neratinib after FDA OK
Puma granted broad label for neratinib after FDA OK
BioPharma Dive
Puma Biotechnology
neratinib
breast cancer
Nerlynx
Flag link:
Puma wins big FDA OK for neratinib after running the gamut with investors
Puma wins big FDA OK for neratinib after running the gamut with investors
Endpoints
Puma Biotechnology
neratinib
breast cancer
Nerlynx
Flag link:
Puma's FDA Decider And Semaglutide's Head-To-Head Battle
Puma's FDA Decider And Semaglutide's Head-To-Head Battle
Seeking Alpha
Puma Biotechnology
FDA
Novo Nordisk
Nerlynx
neratinib
semaglutide
Flag link: